Woodworth Emily 4

4 · BOSTON SCIENTIFIC CORP · Filed Feb 17, 2026

Research Summary

AI-generated summary of this filing

Updated Feb 18, 2026

Boston Scientific SVP Emily Woodworth Exercises Derivatives, Receives Awards

What Happened
Emily Woodworth, SVP, Global Controller and CAO of Boston Scientific (BSX), reported conversions/exercises of derivative awards and receipt of equity awards on Feb 12, 2026. The filing shows conversion/exercise entries for 481 derivative units and two awards/grants totaling 11,655 RSU-type units (6,071 and 5,584). To satisfy tax withholding, 242 shares were surrendered/disposed at $74.12 per share for $17,937. Exercise/conversion entries are recorded at $0.00 per share.

Key Details

Transaction date: February 12, 2026; Form filed February 17, 2026 (appears timely based on provided data).
Actions reported:
- Exercise/conversion of derivative: 481 shares (recorded $0.00).
- Tax withholding/payment: 242 shares disposed at $74.12 → $17,937.
- Additional exercise/conversion entry: 481 shares (recorded $0.00, listed as disposition of a derivative).
- Grants/awards: 6,071 and 5,584 shares reported as acquired (derivative/RSU treatment, $0.00).
Shares owned after the transactions: Not specified in the provided filing excerpt.
Relevant footnotes:
- F1: Each restricted stock unit (RSU) equals one share on issuance.
- F2: Includes ESPP shares acquired June 30, 2025 (most current data).
- F3/F4: Some awarded shares vest/are issued in four equal annual installments beginning Feb 12, 2025 (F3) and Feb 12, 2027 (F4).
- F5: Notes a grant of an option that vests in four equal annual installments beginning Feb 12, 2027.
Transaction codes explanation: M = exercise/conversion of derivative; F = shares surrendered/withheld for tax liability; A = grant/award.

Context

The filing indicates conversions/exercises and the typical tax withholding treatment (shares surrendered rather than cash payment). This is a routine insider equity administration action rather than an open-market purchase or sale intended to express market sentiment.
Because the exercise/conversion is recorded at $0.00, it likely reflects conversion/vesting events (RSU settlement or similar) rather than a cash purchase; 242 shares were used to cover taxes.
No 10% owner or 10b5-1 plan info is indicated in the provided excerpt.

Insider Transaction Report

Form 4

Period: 2026-02-12

BOSTON SCIENTIFIC CORPBSX

Woodworth Emily

SVP, Global Controller and CAO

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2026-02-12+481→ 1,193 total
Tax Payment
Common Stock
2026-02-12$74.12/sh−242$17,937→ 951 total
Exercise/Conversion
Restricted Stock Units
[F1][F3]
2026-02-12−481→ 962 total
Exp: 2028-02-12→ Common Stock (481 underlying)
Award
Restricted Stock Units
[F1][F4]
2026-02-12+6,071→ 6,071 total
Exp: 2030-02-12→ Common Stock (6,071 underlying)
Award
Stock Option (Right to Buy)
[F5]
2026-02-12+5,584→ 5,584 total
Exercise: $74.12Exp: 2036-02-12→ Common Stock (5,584 underlying)

Footnotes (5)

[F1]Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
[F2]Includes shares acquired on June 30, 2025 under the Company's Employee Stock Purchase Plan based upon the most current data available.
[F3]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.
[F4]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
[F5]Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.

Signature

/s/ Susan Thompson, Attorney-in-Fact|2026-02-17

Documents

1 file

4
doc4.xmlPrimary